Professor Michael Barry:

I am not saying that. I am just saying that what is being portrayed in not entirely accurate. Many therapies are being paid for by the public purse that are not being paid for by private insurers. I am sure if you looked hard enough, you would find drugs that are not being paid for by the HSE that are being paid for by private insurers. I will say one thing, however. I went through this very carefully, not for this meeting but another meeting we are having tomorrow, in relation to the 22 cancer drugs that were assessed this year, the vast majority of which were reimbursed. Private health insurers cover five of them. I am saying it is portrayed as if there is this huge inequality, but I do not agree with that. CAR-T cell therapy is one major area, which I mentioned.